INTAIGENT LIMITED
Intaigent Limited is a precision oncology company specializing in AI-driven cancer detection and diagnostics.
Profile
Develops AI-powered blood tests for early cancer detection and precision oncology.
Intaigent Limited is a precision oncology company specializing in AI-driven cancer detection and diagnostics. Founded in the early 2020s, the company has positioned itself at the intersection of biotechnology and artificial intelligence, focusing on non-invasive liquid biopsy tests for early cancer detection. Its flagship product, Shield, is a multi-cancer early detection test that has gained traction in both clinical and direct-to-consumer markets.
The company reported $301.7 million in revenue for Q1 2026, a 48% year-over-year increase, driven by strong performance in oncology and screening segments. Guardant Health has also expanded its biopharma partnerships, leveraging its InfinityAI platform for real-world evidence generation. Recent collaborations include Quest Diagnostics and Manulife, aiming to broaden access to its Shield test in Asia and the U.S. The company raised its 2026 revenue guidance to $1.30-$1.32 billion, reflecting confidence in its growth trajectory.
Who buys this
- Oncology clinics and hospitals
- Biopharmaceutical companies for clinical trials
- Direct-to-consumer health screening markets
- Insurance providers and employers for wellness programs
Strengths and what to watch
Strengths
- Strong revenue growth (48% YoY in Q1 2026) driven by oncology and screening segments
- FDA-approved companion diagnostics for targeted therapies
- Expanding partnerships with Quest Diagnostics and Manulife for broader market access
Watch for
- Regulatory hurdles for new test approvals, especially in international markets
- Competition from other liquid biopsy and AI-driven diagnostic companies
- Dependence on biopharma partnerships for a significant portion of revenue
Recent moves
Key Information
- Founded
- 2020
Frequently Asked Questions
What does INTAIGENT LIMITED do?
INTAIGENT develops AI-powered blood tests for early cancer detection, specializing in precision oncology. Their non-invasive liquid biopsy technology, including the Shield multi-cancer test, helps identify tumors earlier. The company serves clinics, biopharma firms, and direct-to-consumer markets, reporting 48% YoY revenue growth in Q1 2026.
How accurate is the Shield cancer detection test?
While specific accuracy metrics aren't disclosed, Shield is an FDA-approved multi-cancer early detection test using liquid biopsy. It analyzes blood samples with AI to identify tumors, gaining traction in clinical and consumer markets. The technology focuses on non-invasive screening with growing adoption in oncology practices.
What companies partner with INTAIGENT for cancer testing?
INTAIGENT collaborates with Quest Diagnostics and Manulife to expand Shield test access in Asia and the U.S. Their InfinityAI platform also supports biopharma partnerships for clinical trials. These alliances aim to broaden market reach while generating real-world evidence for cancer diagnostics.
How is INTAIGENT performing financially?
INTAIGENT reported $301.7M Q1 2026 revenue, a 48% year-over-year increase. Strong oncology and screening demand prompted raised 2026 guidance to $1.30-$1.32B. Growth stems from Shield test adoption and biopharma partnerships, though revenue depends significantly on these collaborations.
What are the risks of INTAIGENT's cancer detection technology?
Key challenges include regulatory approvals for new tests, especially internationally, and competition from other AI-driven liquid biopsy firms. While revenue grows rapidly, dependence on biopharma partnerships creates vulnerability. The tech must maintain accuracy standards amid expanding clinical and consumer applications.
Can consumers buy INTAIGENT's cancer test directly?
Yes, Shield is available in direct-to-consumer health screening markets alongside clinical use. The test targets employers and insurers for wellness programs too. However, medical follow-up is required for positive results. Expansion through partners like Quest Diagnostics increases consumer access in the U.S. and Asia.
Sources
- investors.guardanthealth.com — Q1 2026 financial results and revenue guidance
- www.informationweek.com — Industry context on tech layoffs and AI realignment
- techcrunch.com — General tech industry trends and competitive landscape
- investor.entegris.com — Benchmarking against other tech-driven healthcare companies